

POLICY NAME	Kepivance (palifermin)	POLICY #	
--------------------	------------------------	-----------------	--

Criteria

Exclusion Criteria – Any of the following prevents coverage

- ☐ **2.1** Use in patients with non-blood related cancers
 - Safety and efficacy have not been established for non-blood related cancers
- ☐ **2.2** Use in patients receiving allogeneic (cells from a different person) stem cell transplant
 - Kepivance was not effective in decreasing the incidence of severe mucositis in the setting of allogeneic stem cell transplant support

Coverage Criteria

- ☐ **1.1** Diagnosis of severe oral mucositis or at risk of developing \geq WHO Grade 3 mucositis
- ☐ **1.2** Diagnosis of blood related cancer
- ☐ **1.3** Patient is currently receiving cancer treatment that causes a decreased immune system response and requiring autologous (cells from same person) stem cell transplant support
- ☐ **1.4** Prescribed by or in consultation with an oncologist (cancer doctor) or hematologist (blood doctor)